Hyatt Celebrates Global Wellness Day 2019 with more than 400 Participating Properties
Reading Time: 4 minutes
Hyatt hotels and spas proudly showcase their wellbeing offerings,
designed to positively impact how colleagues, customers, and community
members feel, fuel and function
CHICAGO–(BUSINESS WIRE)–Hyatt
Hotels Corporation (NYSE: H) today celebrates Hyatt’s landmarks of
wellbeing – Feel, Fuel and Function – by educating and encouraging
colleagues and guests to participate in Global Wellness Day 2019, an
entirely not-for-profit day dedicated raising awareness around what it
means to live well in mind and body. More than 400 properties, including
Hyatt’s Miraval and Exhale brands and the Hyatt’s regional and corporate
offices, are expected to host health and wellness-related events
reflecting their specific destination and local communities.
“At Hyatt, wellbeing is at the core of our DNA,” said Mark Vondrasek,
chief commercial services officer at Hyatt. “We know that wellbeing is
increasingly important to our colleagues, guests, and customers, and
Global Wellness Day provides an opportunity to jointly celebrate our
focus on wellbeing at a global scale. Today, we’re excited to showcase
distinct wellbeing experiences and bring our landmarks of wellbeing –
Feel, Fuel and Function – to life for colleagues and guests at our
hotels around the world.”
From Delhi to Chicago and Zurich to Hong Kong, Hyatt corporate offices
and properties have chosen unique ways to recognize this day. Leading by
example, Hyatt’s global headquarters will be celebrating Global Wellness
Day with colleagues by offering a guided yoga and meditation class and a
healthy breakfast to start the day. Additionally, knowing guests and
colleagues’ alike put great value in their wellbeing, properties across
the world were passionate about planning celebrations for Global
Wellness Day. A few examples include the following:
Asia-Pacific Region
-
Alila
Ubud Bali: The hotel team will provide healthy meals
for children using ingredients from the property’s organic garden and
donating them to the KIM foundation, which helps children with special
needs. Additionally, guests and villagers from Banjar Bayad are
invited to celebrate with a Zumba class at their Sculpture Garden. -
Hyatt
Place and Hyatt House Yinchuan Dayuecheng: This
dual-branded property in China is promoting a Family Day Photo Contest
where all colleagues will be asked to enjoy a family dinner at home
and share photos with colleagues. Additionally, they are hosting a Get
Up and Step Up Challenge for colleagues, where colleagues will use
WeChat to count their steps in the morning, promoting efforts to start
each day with exercise.
Europe-Middle East-Southwest Asia Region
-
Andaz
Amsterdam Prinsengracht: The property will put on a 5k
run for both colleagues and guests, offering healthy snacks and
refreshments at the end of the race. Colleagues will have the option
to also participate in yoga sessions and a one-hour fitness and food
consultation from a health professional. -
Park
Hyatt Istanbul: During the week leading up to Global
Wellness Day, the hotel invited a popular dietitian to deliver healthy
eating tips during their wellness event, where colleagues and guests
enjoyed detox shots and relaxation exercises at the pool.
The Americas
-
Manchester
Grand Hyatt San Diego: The property will host a
wellness fair for colleagues, with events that include healthy cooking
demonstrations, customized stretching exercises, a mandala coloring
corner and a relaxation room offering chair massages and mini facials. -
Hyatt
Regency Lost Pines: The Cedar Creek, Texas property
will provide an ambient quiet room featuring meditative music, yoga
mats and candles for colleagues and guests, while also distributing
reusable water bottles, sleep patches, sunscreen and signature
smoothies in the lobby. Camp Hyatt, the resort’s activity program for
kids, will also provide a beginner’s yoga class for children, along
with other wellness activities. -
The
Beekman, a Thompson Hotel: The New York City property
will host a colleague walk over the neighboring Brooklyn Bridge, while
also offering guided mediation and morning yoga. -
Hyatt
Centric Waikiki Beach: Colleagues at the Hawaiian
property will join together for a group hike on Diamond Head Volcano. -
Exhale:
To bring awareness to their many spa and fitness offerings, all Exhale
locations will be allowing guests and members to bring a friend for
free to fitness classes on Global Wellness Day. -
Miraval
Resorts: Both Miraval Austin and Miraval Arizona will
be creating a mindful moment for guests at their central gathering
place, around their custom made Earth Gong. Guests will be invited to
gather at the Gong at 12pm, where a poem from Thich Nhat Han will be
recited, allowing guests to tune in, slow down, and take in the
vibration of the gong. They will also be invited to take turns banging
the gong and sharing their intentions on how they will take steps
toward living a healthier, more balanced life, the key purpose of
Global Wellness Day.
Follow #globalwellnessday and #GWD2019 to see how participants are
celebrating Global Wellness Day 2019. And for more information around
Hyatt’s commitment to wellbeing, please visit hyatt.com/aboutus/wellbeing.
The term “Hyatt” is used in this release for convenience to refer to
Hyatt Hotels Corporation and/or one or more of its affiliates.
About Hyatt Hotels Corporation
Hyatt Hotels Corporation, headquartered in Chicago, is a leading global
hospitality company with a portfolio of 19 premier brands. As of March
31, 2019, the Company’s portfolio included more than 850 properties in
over 60 countries across six continents. The Company’s purpose to care
for people so they can be their best informs its business decisions and
growth strategy and is intended to attract and retain top colleagues,
build relationships with guests and create value for shareholders. The
Company’s subsidiaries develop, own, operate, manage, franchise, license
or provide services to hotels, resorts, branded residences, vacation
ownership properties, and fitness and spa locations, including under the Park
Hyatt®, Miraval®, Grand Hyatt®, Alila®, Andaz®, The
Unbound Collection by Hyatt®, Destination®, Hyatt
Regency®, Hyatt®, Hyatt Ziva
, Hyatt
Zilara, Thompson Hotels®, Hyatt
Centric®, Hyatt House®, Hyatt Place®, Joie
de Vivre®, tommie, Hyatt
Residence Club® and Exhale® brand names,
and operates the World of Hyatt® loyalty program that provides
distinct benefits and exclusive experiences to its valued members. For
more information, please visit www.hyatt.com.
Contacts
Jennifer Rubin
Hyatt
312 780 5808
[email protected]
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
